Thursday Edition
Friday Edition
Head-to-head (to head) studies
Switching/sequencing studies
New analyses of DMT effectiveness
Use of gadolinium – consensus statement
Pregnancy rate on the increase in women with MS Read More
Latest News
ECTRIMS 2017 DAILY REPORT – FRIDAY EDITION
October 27, 2017ECTRIMS 2017 DAILY REPORT – THURSDAY EDITION
October 26, 2017Cladribine: intermittent immunosuppression in MS
September 21, 2017SPECIAL REPORT
The next disease-modifying therapy (DMT) expected to become available in Canada is cladribine, an oral agent initially developed a decade ago (see The return of cladribine in RRMS, NeuroSens, August 23, 2017). The drug was approved by the European Medicines Agency in June, and is currently in review with Health Canada.